Dipòsit Digital de Documents de la UAB 18 registres trobats  1 - 10següent  anar al registre: La cerca s'ha fet en 0.00 segons. 
1.
469.5 KB Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes / Martin, Roman (University Medical Center Göttingen) ; Acha, Pamela (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ganster, Christina (University Medical Center Göttingen) ; Palomo Sanchís, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Dierks, Sascha (University Medical Center Göttingen) ; Fuster-Tormo, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ademà, Vera (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Gómez-Marzo, Paula (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; De Haro, Nuri (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Solanes, Neus (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Shirneshan, Katayoon (University Medical Center Göttingen) ; Flach, Johanna (University Medical Center Göttingen) ; Braulke, Friederike (University Medical Center Göttingen) ; Schanz, Julie (University Medical Center Göttingen) ; Kominowski, Arkadiusz (University Medical Center Göttingen) ; Stromburg, Martin (University Medical Center Göttingen) ; Brockmann, Alina (University Medical Center Göttingen) ; Trümper, Lorenz (University Medical Center Göttingen) ; Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Haase, Detlef (University Medical Center Göttingen) ; Universitat Autònoma de Barcelona
2018 - 10.1002/ajh.25089
American Journal of Hematology, Vol. 93 (april 2018) , p. E152-E154  
2.
9 p, 468.5 KB Preliminary data on COVID-19 in patients with hemoglobinopathies : A multicentre ICET-A study / de Sanctis, V. (Pediatric and Adolescent Outpatient Clinic. Quisisana Hospital) ; Canatan, D. (Antalya Genetic Diseases Diagnostic Center) ; Vives Corrons, Juan Luís (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Karimi, M. (Hematology Research Center. Shiraz University of Medical Sciences) ; Daar, S. (Department of Haematology. College of Medicine and Health Sciences. Sultan Qaboos University) ; Kattamis, C. (First Department of Paediatrics. National Kapodistrian University of Athens) ; Soliman, A.T. (Department of Pediatrics. University of Alexandria) ; Wali, Y. (Department of Paediatrics. Faculty of Medicine. Alexandria University) ; Alkindi, S. (Department of Haematology. College of Medicine and Health Sciences. Sultan Qaboos University) ; Huseynov, V. (Center of Thalassemia) ; Nasibova, A. (Center of Thalassemia) ; Tiryaki, T.O. (İstanbul University. Faculty of Medicine. Department of Hematology) ; Evim, M.S. (Uludag University. Medical Faculty. Dept. of Pediatric Hematology) ; Gunes, A.M. (Uludag University. Medical Faculty. Dept. of Pediatric Hematology) ; Karakas, Z. (Istanbul University. Istanbul Faculty of Medicine. Pediatric Hematology / Oncology) ; Christou, S. (Archibishop Makarios III Hospital. Thalassaemia Clinic) ; Campisi, S. (UOSD Thalassemia. Umberto I° Hospital) ; Zarei, T. (Hematology Research Center. Shiraz University of Medical Sciences) ; Khater, D. (Department of Pediatrics. Sultan Qaboos University) ; Oymak, Y. (Dr. Behcet Uz Children's Hospital) ; Kaleva, V. (Expert Center for Coagulopathies and Rare Anemias) ; Stoyanova, D. (Pediatric Hematoncology. University Hospital "Tzaritza Giovanna - ISUL") ; Banchev, A. (Pediatric Hematoncology. University Hospital "Tzaritza Giovanna - ISUL") ; Galati, M.C. (Pediatric Haematoncology. Pugliese-Ciaccio Hospital) ; Yassin, M.A. (Hematology Section. National Center for Cancer Care and Research. Hamad Medical Corporation. (HMC)) ; Kakar, S. (Pediatric Hematology Oncology. Department of Pediatrics. Dayanand Medical College and Hospital) ; Skafida, M. (First Department of Paediatrics. National Kapodistrian University of Athens) ; Kilinc, Y. (Pediatric Hematology Department. Çukurova University) ; Alyaarubi, S. (Pediatric Endocrinology Unit. Child Health Department. College of Medicine and Health Sciences. Sultan Qaboos University) ; Verdiyevas, N. (Center of Thalassemia) ; Stoeva, I. ("Screening and Functional Endocrine Diagnostics". University Paediatric Hospital) ; Raiola, G. (Department of Paediatrics. Pugliese-Ciaccio Hospital) ; Mariannis, D. (Royal Lancaster Infirmary) ; Ruggiero, L. (Pediatrician) ; Di Maio, S. (Emeritus Director in Pediatrics. "Santobono-Pausilipon" Children's Hospital) ; Universitat Autònoma de Barcelona
Objectives: This study aims to investigate, retrospectively, the epidemiological and clinical characteristics, laboratory results, radiologic findings, and outcomes of COVID-19 in patients with transfusion-dependent β thalassemia major (TM), β-thalassemia intermedia (TI) and sickle cell disease (SCD). [...]
2020 - 10.4084/MJHID.2020.046
Mediterranean Journal of Hematology and Infectious Diseases, Vol. 12 Núm. 1 (2020) , p. e2020046  
3.
16 p, 1.5 MB Risk factors and outcome of COVID-19 in patients with hematological malignancies / Piñana, J.L. (Hospital Universitari i Politècnic La Fe de Valencia) ; Martino, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ; García-García, I. (Hematology División. Hospital Ramon y Cajal) ; Parody, R. (Institut Català d'Oncologia) ; Morales, M.D. (Hematology División. Hospital de Guadalajara) ; Benzo, G. (Hematology División. Hospital la Princesa) ; Gómez-Catalan, I. (Complejo Hospitalario Universitario de Albacete) ; Coll, R. (Hospital Universitari de Girona Doctor Josep Trueta) ; De La Fuente, I. (Hospital Clínico Universitario (Valladolid)) ; Luna, A. (Hematology División. Hospital Ramon y Cajal) ; Merchán, B. (Hematology División. Hospital de Guadalajara) ; Chinea, A. (Hematology División. Hospital Ramon y Cajal) ; De Miguel, D. (Hematology División. Hospital de Guadalajara) ; Serrano, A. (Complejo Hospitalario Universitario de Albacete) ; Pérez, C. (Hospital Clínico Universitario (Valladolid)) ; Diaz, C. (Hematology División. Hospital Carlos Haya) ; Lopez, J.L. (Hematology División. Hospital Fundación Jiménez Díaz) ; Saez, A.J. (Hematology División. Hospital Ramon y Cajal) ; Bailen, R. (Hospital Gregorio Marañón (Madrid)) ; Zudaire, T. (Hematology División. Hospital de Navarra) ; Martínez, D. (Hematology División. Hospital A Coruña) ; Jurado, M. (Hematology División. Hospital Virgen de la Nieves) ; Calbacho, M. (Hospital 12 de Octubre (Madrid)) ; Vázquez, L. (Hematology División. Hospital Universitario de Salamanca) ; García Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau) ; Fox, Maria Laura (Vall d'Hebron Institut d'Oncologia) ; Pimentel, A.I. (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ; Bautista, G. (Hospital Puerta de Hierro (Madrid)) ; Nieto, Adoración (Hematology División. Hospital de Vigo) ; Fernandez, P. (Hematology División. Hospital General de Alicante) ; Vallejo, J.C. (Hematology División. Hospital de Donostia) ; Solano, C. (Hospital Clínic Universitari (València)) ; Valero, M. (Hematology División. Hospital Arnau de Vilanova) ; Espigado, I. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Saldaña, R. (Hematology División. Hospital de Jerez) ; Sisinni, L. (Hospital Universitario La Paz (Madrid)) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Jiménez, María José (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Trabazo del Castillo, María (Institut d'Investigació Biomèdica Sant Pau) ; Gonzalez-Vicent, M. (Pediatric División. Hospital Niño Jesús) ; Fernández, N. (Hematology División. Hospital Marqués de Valdecilla) ; Talarn, C. (Hospital Universitari Joan XXIII de Tarragona) ; Montoya, M.C. (Complejo Hospitalario Universitario de Albacete) ; Cedillo, A. (Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH)) ; Sureda, A. (Institut Català d'Oncologia) ; Universitat Autònoma de Barcelona
Background: Prognostic factors of poor outcome in patients with hematological malignancies and COVID-19 are poorly defined. Patients and methods: This was a Spanish transplant group and cell therapy (GETH) multicenter retrospective observational study, which included a large cohort of blood cancer patients with laboratory-confirmed SARS-CoV-2 infection through PCR assays from March 1st 2020 to May 15th 2020. [...]
2020 - 10.1186/s40164-020-00177-z
Experimental Hematology & Oncology, Vol. 9 Núm. 1 (25 2020) , p. 21  
4.
13 p, 1.0 MB Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia : A comparative study of the ALWP EBMT / Sanz, Jaime (CIBERONC. Instituto Carlos III) ; Galimard, J.E. (EBMT Paris Office. Hospital Saint Antoine) ; Labopin, M. (Department of Hematology. Hopital Saint Antoine. Sorbonne University) ; Afanasyev, B. (First State Pavlov Medical University of St. Petersburg. Raisa Gorbacheva Mem. Research Institute for Paediatric Oncology. Hematology. and Transplantation) ; Angelucci, E. (Department of Haematology. IRCCS Ospedale Policlinico San Martino) ; Ciceri, F. (Haematology and BMT) ; Blaise, D. (Programme de Transplantation and Therapie Cellulaire. Centre de Recherche en Cancérologie de Marseille. Institut Paoli Calmettes) ; Cornelissen, J.J. (Department of Hematology. Erasmus MC Cancer Institute. University Medical Center Rotterdam) ; Meijer, E. (Department of Hematology (Br 250). VU University Medical Center) ; Diez-Martin, J.L. (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ; Koc, Y. (Stem Cell Transplant Unit. Medical Park Hospitals) ; Rovira Tarrats, Montserrat (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Castagna, L. (Transplantation Unit. Department of Oncology and Haematology. Istituto Clinico Humanitas) ; Savani, B.N (Vanderbilt University Medical Center) ; Ruggeri, A. (Ospedale Pediatrico Bambino Gesù (Roma, Itàlia)) ; Nagler, A. (ALWP of the EBMT Office. Saint Antoine Hospital) ; Mohty, M. (Department of Hematology. Hopital Saint Antoine. Sorbonne University) ; Universitat Autònoma de Barcelona
Background: The use of post-transplant cyclophosphamide (PTCy) is highly effective in preventing graft-versus-host disease (GVHD) in the haploidentical (Haplo) transplant setting and is being increasingly used in matched sibling (MSD) and matched unrelated (MUD) transplants. [...]
2020 - 10.1186/s13045-020-00882-6
Journal of hematology & oncology, Vol. 13 Núm. 1 (june 2020) , p. 46  
5.
10 p, 911.0 KB Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma / Davies, A. (Cancer Research UK Centre. Centre for Cancer Immunology. Faculty of Medicine. University of Southampton. Southampton General Hospital) ; Trask, P. (Genentech Inc.) ; Demeter, J. (Semmelweis University) ; Florschütz, A. (Städtisches Klinikum Dessau) ; Hänel, M. (Klinikum Chemnitz gGmbH) ; Kinoshita, T. (Aichi Cancer Center Hospital) ; Pettengell, R. (St George's University) ; Quach, H. (University of Melbourne and St. Vincent's Hospital) ; Robinson, S. (Bristol Haematology and Oncology Centre) ; Sadullah, S. (James Paget Hospital) ; Sancho, Juan-Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Udvardy, M. (Medical and Health Science Centre. University of Debrecen) ; Witzens-Harig, M. (Uniklinik Heidelberg) ; Knapp, A. (F. Hoffmann-La Roche Ltd) ; Liu, W. (F. Hoffmann-La Roche Ltd) ; Universitat Autònoma de Barcelona
Health-related quality of life was a secondary endpoint in the phase III GALLIUM study in previously untreated patients with follicular lymphoma who were treated with rituximab- or obinutuzumab-chemotherapy. [...]
2020 - 10.1007/s00277-020-04021-6
Annals of Hematology, Vol. 99 Núm. 12 (december 2020) , p. 2837-2846  
6.
11 p, 1.4 MB Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma / Timmerman, John (UCLA Medical Center) ; Herbaux, Charles (Centre Hospitalier Régional Universitaire de Lille) ; Ribrag, Vincent (Institut Gustave Roussy) ; Zelenetz, Andrew D. (Memorial Sloan Kettering Cancer Center) ; Houot, Roch (Unité dʼInvestigation Clinique) ; Neelapu, Sattva S. (The University of Texas MD Anderson Cancer Center) ; Logan, Theodore (Indiana University) ; Lossos, Izidore S. (Sylvester Comprehensive Cancer Center) ; Urba, Walter (Providence Cancer Center) ; Salles, Gilles (Université de Lyon) ; Ramchandren, Radhakrishnan (Karmanos Cancer Institute) ; Jacobson, Caron (Harvard Medical School) ; Godwin, John (Providence Cancer Center) ; Carpio, Cecilia (Universitat Autònoma de Barcelona. Departament de Medicina) ; Lathers, Deanne (Bristol-Myers Squibb) ; Liu, Yali (Bristol-Myers Squibb) ; Neely, Jaclyn (Bristol-Myers Squibb) ; Suryawanshi, Satyendra (Bristol-Myers Squibb) ; Koguchi, Yoshinobu (Providence Cancer Center) ; Levy, Ronald (Stanford University School of Medicine)
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity in preclinical models, and may enhance cytotoxic activity of rituximab. [...]
2020 - 10.1002/ajh.25757
American Journal of Hematology, Vol. 95 (february 2020) , p. 510-520  
7.
4 p, 736.7 KB Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia / Genescà, Eulàlia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Lazarenkov, A. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Morgades, Mireia. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Berbis, G. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ruíz-Xivillé, N. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Gómez-Marzo, P. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ribera, J. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Juncà, J. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; González-Pérez, A. (Institute for Research in Biomedicine (IRB Barcelona)) ; Mercadal, Santiago (Clinical Hematology Service, Hospital Duran i Reynals-ICO, Hospitalet del LLobregat) ; Guardia, R. (Hospital Universitari de Girona Doctor Josep Trueta) ; Artola, M. T. (Hospital Universitario de Donostia. Clinical Hematology Service) ; Moreno, M. J. (Clinical Hematology Service, Hospital Vírgen de la Victoria) ; Martínez-López, J. (Hospital 12 de Octubre (Madrid)) ; Zamora, L. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Barba, Pere (Vall d'Hebron Institut d'Oncologia) ; Gil, Cristina (Clinical Hematology Service, Hospital General de Alicante) ; Tormo, M. (Hospital Clínic Universitari (València)) ; Cladera, A. (Clinical Hematology Service, Hospital Son Llàtzer) ; Novo, A. (Clinical Hematology Service, Hospital Son Espases) ; Pratcorona, M. (Institut d'Investigació Biomèdica Sant Pau) ; Nomdedeu, Josep (Institut d'Investigació Biomèdica Sant Pau) ; González-Campos, J. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Almeida, M. (Universidad de Salamanca. Banco Nacional de ADN Carlos III) ; Cervera, J. (Biobanco de la Fe, Instituto de Investigación Sanitaria La Fe (IIS La Fe)) ; Montesinos, Pau (Hospital Universitari i Politècnic La Fe (València)) ; Batlle, M. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Vives, S. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ; Feliu, E. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Solé, F. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Orfao, A. (Hospital Clínico Universitario (Salamanca)) ; Ribera, J. M. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
Recurrent deletions of the CDKN2A/ARF/CDKN2B genes encoded at chromosome 9p21 have been described in both pediatric and adult acute lymphoblastic leukemia (ALL), but their prognostic value remains controversial, with limited data on adult T-ALL. [...]
2018 - 10.1186/s13045-018-0639-8
Journal of hematology & oncology, Vol. 11 (july 2018)  
8.
15 p, 464.3 KB Bispecific T-cell engaging antibodies in B-cell precursor acute lymphoblastic leukemias : focus on blinatumomab / Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Genescà, Eulàlia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ribera Salas, Jordi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
Bispecific T-cell engaging antibodies are constructs engineered to bind to two different antigens, one to a tumor-specific target and the other to CD3-positive T cells or natural killer (NK) cells. Blinatumomab engages CD19 and CD3, performing effective serial lysis. [...]
2020 - 10.1177/2040620720919632
Therapeutic Advances in Hematology, Vol. 11 (may 2020)  
9.
11 p, 623.1 KB Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia / Megías-Vericat, Juan Eduardo (Hospital Universitari i Politècnic La Fe de Valencia) ; Martínez-Cuadrón, David (CIBERONC, Instituto Carlos III, Madrid, Spain) ; López, Joaquín Martínez (Hospital Universitario 12 de Octubre, UCM, CNIO, CIBERONC, Madrid, Spain) ; Bergua, Juan Miguel (Hospital San Pedro de Alcántara) ; Tormo, Mar (Hospital Clínic Universitari (València)) ; Serrano, Josefina (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ; González, Ataulfo (Hospital Clínico San Carlos (Madrid)) ; de Oteyza, Jaime Pérez (Hospital de Madrid Norte Sanchinarro, Madrid, Spain) ; Vives Polo, Susana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Vidriales, Belén (Complejo Asistencial Universitario de Salamanca, Salamanca, Spain) ; Herrera, Pilar (Hospital Universitario Ramón y Cajal, Madrid, Spain) ; Vera, Juan Antonio (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ; Martínez, Aurelio López (Hospital Arnau de Vilanova (València)) ; de la Fuente, Adolfo (MD Anderson Cancer Center, Madrid, Spain) ; Amador, Ma Lourdes (Hospital de Montecelo, Pontevedra, Spain) ; Hernández-Rivas, José-Ángel (Hospital Universitario Infanta Leonor, Universidad Complutense de Madrid, Madrid, Spain) ; Fernández, Ma Ángeles (Hospital Xeral Cies, Vigo, Spain) ; Cerveró, Carlos Javier (Hospital Virgen de la Luz, Cuenca, Spain) ; Morillo, Daniel (Hospital Universitario Fundación Jiménez Díaz) ; Campo, Pilar Hernández (Vivia Biotech, Tres Cantos, Madrid, Spain) ; Gorrochategui, Julián (Vivia Biotech, Tres Cantos, Madrid, Spain) ; Primo, Daniel (Vivia Biotech, Tres Cantos, Madrid, Spain) ; Rojas, José Luis (Vivia Biotech, Tres Cantos, Madrid, Spain) ; Guenova, Margarita (Specialized Hospital for Active Treatment of Hematological Diseases, Sofía, Bulgaria) ; Ballesteros, Joan (Vivia Biotech, Tres Cantos, Madrid, Spain) ; Sanz, Miguel (CIBERONC, Instituto Carlos III, Madrid, Spain) ; Montesinos, Pau (CIBERONC, Instituto Carlos III, Madrid, Spain) ; Universitat Autònoma de Barcelona
Induction schedules in acute myeloid leukemia (AML) are based on combinations of cytarabine and anthracyclines. The choice of the anthracycline employed has been widely studied in multiple clinical trials showing similar complete remission rates. [...]
2019 - 10.4084/MJHID.2019.016
Mediterranean Journal of Hematology and Infectious Diseases, Vol. 11 (march 2019)  
10.
12 p, 548.1 KB Mosaicism in Fanconi anemia : concise review and evaluation of published cases with focus on clinical course of blood count normalization / Nicoletti, Eileen (Rocket Pharmaceuticals, Inc., New York) ; Rao, Gayatri (Rocket Pharmaceuticals, Inc., New York, NY USA) ; Bueren, Juan A. (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ; Río, Paula (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ; Navarro Ordóñez, Susana (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ; Surrallés i Calonge, Jordi (Institut d'Investigació Biomèdica Sant Pau) ; Choi, Grace (Rocket Pharmaceuticals, Inc., New York) ; Schwartz, Jonathan D. (Rocket Pharmaceuticals, Inc., New York) ; Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia
Fanconi anemia (FA) is a DNA repair disorder resulting from mutations in genes encoding for FA DNA repair complex components and is characterized by variable congenital abnormalities, bone marrow failure (BMF), and high incidences of malignancies. [...]
2020 - 10.1007/s00277-020-03954-2
Annals of Hematology, Vol. 99 (february 2020) , p. 913-924  

Dipòsit Digital de Documents de la UAB : 18 registres trobats   1 - 10següent  anar al registre:
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.